Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Grail Inc.
The Illumina Shareholder Votes Are In, And Nobody Got What They Wanted
Carl Icahn was successful in ousting Illumina’s chair, however its CEO, Francis deSouza remains. Both analysts and investors believe this could further encourage Illumina to divest Grail.
Pfizer/Seagen Merger Seems Set To Clear As US FTC Sticks To Traditional Review
Pink Sheet infographic breaks down the big pharma deals and required divestitures over the past four years. Seagen reports that Pfizer's acquisition of the company is expected to close late this year or in early 2024.
Activist Investor Calls For Sanity As FTC Rejects Grail-Illumina Deal
Illumina faces a difficult decision now that the US FTC has formally rejected its attempt to re-acquire Grail, the sequencing company it originally sold in 2016. The FTC and European regulators say the merger would stifle competition but the company plans to appeal the ruling.
Contrast Agent, Liquid Biopsy Tool Or Treatment? Earli Might Deliver All Three At Once
The company has developed a technology that uses engineered DNA to reprogram cancer cells, forcing them to produce substances that could be used to help image, detect or even destroy them.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Drug Discovery Technologies
- Drug Discovery Technologies
- Other Names / Subsidiaries
- GRAILBio Cirina Ltd
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.